Mark G. Foletta
At a glance: Mark G. Foletta is Director at Dexcom (DXCM). Their latest SEC Form 4, filed Aug 4, 2026, reported a sale of $160K. On file: 0 purchase lines ($0) and 6 sale lines ($742K).
Disclosed holdings: about $3.9M of DXCM stock: 48,852 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Aug 4, 2026), valued at the Nov 19, 2026 close of $79.36. This counts only DXCM shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Amn Healthcare Services Inc (AMN); Director at Dexcom Inc (DXCM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Mark G. Foletta's InsiderPrint
7 trades from SEC Form 4 filings, 2024 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 3 times a year, typically $62K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (1)
- Dent inward: a sale (6)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Erika T. DavisSee Remarks · PFGC · 97% match
- Anthony FolgerDirector · CSPI · 96% match
- MPM Oncology Innovations Fund LP10% Owner · AKTS · 95% match
- Kevin TanCFO · SLDB · 95% match
- George R. NebleDirector · EVER · 95% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2024
From the SEC's insider data sets: each open-market buy by Mark G. Foletta, matched to how the stock did over the next 90 days against the S&P 500.
0 of 1 buy beat the S&P 500 (0%), median -15.5% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| AMN | Mar 7, 2024 | -15.5% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 4SEC | DXCMDexcom Inc | Sell Plan | 2,00050,852 held (−4%) | $80.00 | $160K | -0.8% |
| Aug 4SEC | DXCMDexcom Inc | Sell Plan | 2,00048,852 held (−4%) | $85.32 | $171K | -7.0% |
| Jun 17SEC | DXCMDexcom Inc | Sell Plan | 3,80153,051 held (−7%) | $74.10 | $282K | +7.1% |
| Jun 17SEC | DXCMDexcom Inc | Sell Plan | 19952,852 held (−0%) | $74.82 | $15K | +6.1% |
| Jun 17SEC | AMNAmn Healthcare Services Inc | Sell Plan | 1,68119,917 held (−8%) | $31.07 | $52K | +13.7% |
| Jun 17SEC | AMNAmn Healthcare Services Inc | Sell Plan | 2,00017,917 held (−10%) | $31.07 | $62K | +13.7% |
- Sell
Director Mark G Foletta sold $160K of DXCM at $80.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark G Foletta sold $171K of DXCM at $85.32 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark G Foletta sold $282K of DXCM at $74.10 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark G Foletta sold $15K of DXCM at $74.82 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark G Foletta sold $52K of AMN at $31.07 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Mark G Foletta sold $62K of AMN at $31.07 — pre-scheduled 10b5-1 plan sale.
Follow Mark G. Foletta
Get one email when Mark G. Foletta files a new purchase or sale. Free.
At most one email a day about Mark G. Foletta, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.